Tagged with Italy,

Pharma Alexander Zehnder discusses Sanofi’s sizable contribution to the Italian economy, manufacturing in Italy, and the country’s labyrinthine drug approval processes. What have been your main areas of focus and priorities since your appointment as head of Sanofi’s Italy and Malta operations in October 2014? Sanofi is in the midst of a transition from…

Pharma Country Manager Giovanna Labbate talks how Gedeon Richter aims to become the point of reference for women’s health in Italy, the successful launch of ESMYA, and the establishment of the affiliate five years ago. The Gedeon Richter Italy affiliate was established in 2011. What was the rationale behind starting this…

Pharma Mr. Aldo Braca discusses the competitive CDMO landscape in Italy, the importance of nurturing a community of employees, and the optimistic growth trend for the company powered by investment and innovation. This year, BSP celebrated its ten-year anniversary, congratulations! What were the key objectives that you have accomplished since the…

Pharma Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing Sandoz’s historic engagement with the Italian market? Sandoz began marketing in Italy back in 2000. My own background, meanwhile, was…

Pharma Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to become a market leader in Italy. A lot has been happening with Novartis globally lately: with big changes to the…

Pharma Pharmaceuticals Giuseppe Martini, President at the National Technological Cluster: Advanced Life Sciences in Italy (ALISEI) discusses the founding of the ALISEI cluster, its main missions and how it helps Italy to promote itself as a research destination on a pan-European level. Mr. Martini, can you give our readers a brief overview…

Pharma Elena Tremoli, Scientific Director at Centro Cardiologico Monzino, explains the importance of both applied and cardiovascular research in Italy, and how prevention in this area will be key in the future. Centro Cardiologico Monzino is the only institute of excellence in Europe exclusively devoted to cardiovascular diseases. Can you describe…

Pharma Pharmaceuticals Eugenio Aringhieri discusses Dompé’s shift in strategy towards opthalmology, instilling an innovation mindset, and broadening the company’s international horizons. Since we last interviewed you in 2009 a lot has happened: you were made European CEO in 2015 for having steered Dompé through considerable renewal and restructuring, the company also embarked…

Pharma Pier Mannuccio Mannucci, Scientific Director of the Policlinico Foundation, describes some of the challenges the scientific community currently faces in Italy and what actions need to be taken to overcome these. He goes on to discuss the main objectives of the foundation and how the recent restructuring will provide better…

Pharma The President and MD of Abiogen Pharma discusses his family company’s recent milestones, the reasons for persisting with local manufacturing, and the benefits of international partnerships. You created Abiogen back in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition and build…

Pharma Ferring Italy’s CEO discusses the affiliate’s successful management strategy, new products, new partnerships, and the potential of the Italian market. When we last interviewed you in 2009, you were focused on: (1) reinforcing the local organization’s structure, (2) successfully launching Firmagon, and (3) forging new partnerships in the IBD field.…

Pharma Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what he sees as the keys to unlocking Italy’s potential for innovation over the next few years. Having worked for Amgen…